ACET - Adicet Bio Inc
NYSE * Health Care * Biotechnology
$7.90
$-0.38 (-4.59%)
About Adicet Bio Inc
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin's lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts.
ACET Key Statistics
Market Cap
$79.49M
P/B Ratio
0.73
EPS
$-20.00
Revenue Growth
-1.0%
Employees
152
How ACET Compares to Peers
P/E Rank
N/A
of 5
Margin Rank
N/A
of 5
Growth Rank
#6
of 6
Size Rank
#6
of 6
Adicet Bio Inc Company Information
- Headquarters
- Massachusetts; U.S.A
- Website
- www.adicetbio.com
- Sector
- Health Care
- Industry
- Biotechnology